The earnings call presented a mixed outlook. There was strong performance from the Integrity product line and progress with Cingal, but notable challenges with Hyalofast's clinical trial results and a decline in overall revenue and gross margin.

Company Guidance

During Anika's second quarter 2025 earnings call, the company reported that its quarterly performance was in line with expectations, and it remains on track to meet its full-year guidance. The company experienced an 8% decline in total revenue to $28.2 million compared to the same period in 2024, primarily due to a 13% drop in the OEM channel, while the commercial channel revenue remained flat. The regenerative solutions segment, driven by the Integrity Implant System, grew by 41% year-over-year, achieving five consecutive quarters of sequential growth. Despite some manufacturing challenges earlier in the quarter, Anika managed to resolve these issues, and expects gross margins to improve to 58-59% in the second half of the year. The company is maintaining its full-year financial outlook, projecting commercial channel revenue growth between 12% to 18% and an adjusted EBITDA guidance range of negative 3% to positive 3%. Anika also plans to submit the third and final PMA module for Hyalofast in the second half of the year, aiming for a commercial timeline extension to 2027 to allow for thorough FDA review.

Integrity Outperforms Expectations

Integrity has already exceeded its full-year 2024 performance, is on track to more than double in 2025, and led to a 41% growth in Regenerative Solutions revenue this quarter.

Cingal Progress

Meaningful progress was made toward NDA filing for Cingal, with plans to initiate the bioequivalence study by year-end.

Operating Expense Reduction

Total operating expenses were reduced by 17% year-over-year, reflecting disciplined cost management.

Strong Cash Position

Ended the second quarter with $53 million in cash and no debt.

Anika Therapeutics (ANIK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ANIK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.21 / -	-0.25	―	―	―
Jul 30, 2025	2025 (Q2)	-0.26 / -0.13	0.17	-176.47% (-0.30)
May 09, 2025	2025 (Q1)	-0.09 / -0.06	0.09	-166.67% (-0.15)
Mar 12, 2025	2024 (Q4)	-0.23 / -0.03	0.05	-160.00% (-0.08)
Oct 31, 2024	2024 (Q3)	0.09 / -0.25	0	―
Aug 08, 2024	2024 (Q2)	0.07 / 0.17	0.06	183.33% (+0.11)
May 08, 2024	2024 (Q1)	-0.08 / 0.09	-0.36	125.00% (+0.45)
Mar 13, 2024	2023 (Q4)	-0.23 / 0.05	-0.34	114.71% (+0.39)
Nov 02, 2023	2023 (Q3)	-0.35 / 0.00	-0.29	―
Aug 08, 2023	2023 (Q2)	-0.32 / 0.06	-0.2	130.00% (+0.26)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ANIK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$11.16	$8.10	-27.42%
May 09, 2025	$14.74	$11.64	-21.03%
Mar 12, 2025	$17.11	$15.21	-11.10%
Oct 31, 2024	$24.68	$17.11	-30.67%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Anika Therapeutics (ANIK) report earnings?

Anika Therapeutics (ANIK) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Anika Therapeutics (ANIK) earnings time?

Anika Therapeutics (ANIK) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ANIK EPS forecast?

ANIK EPS forecast for the fiscal quarter 2025 (Q3) is -0.21.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing